{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-018425","form_type":"8-K","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2023-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.941328+00:00","generated_at":"2026-06-14T23:48:01.620112+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioventus Q1 net loss $100M on $78.6M impairment; Adj. EBITDA $17M beats expectations","bullets":["Net sales $119.1M (+1.5% YoY); net loss from cont. ops. $100.0M vs $14.4M loss prior year.","Adjusted EBITDA $17.0M vs $7.2M prior year, exceeding expectations; non-GAAP operating income $13.5M vs $1.9M.","Non-cash $78.6M impairment write-down on Wound Business now classified as held for sale.","Signed purchase agreement to divest Wound Business (annual rev ~$40M, Adj. EBITDA ~$5M) on May 10, 2023.","Cash $47.1M, debt $445.6M; FY 2023 Adj. EBITDA guidance at least $68M excluding Wound Business."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-018425","json":"https://secwatch.observer/filing/0001628280-23-018425.json","markdown":"https://secwatch.observer/filing/0001628280-23-018425.md","text":"https://secwatch.observer/filing/0001628280-23-018425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023018425/0001628280-23-018425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023018425/bvs-20230516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T23:48:01.620112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f1163bad307056bd27d71223ab1ee73209de357","claim":"Bioventus Inc. reported three months ended April 1, 2023 results: revenue $119.1 million, net income $100.0 million, EPS $1.28. Guidance reaffirmed.","evidence_excerpt":"Company\"), a global leader in innovations for active healing, today reported financial results for the three months ended April 1, 2023. Q1 Financial Summary: • Net Sales of $119.1 million, up $1.8 million, or 1.5%, year-over-year as reported (1.9% constant currency*) • Net Loss from continuing operations of $100.0 million, compared to Net Loss from continuing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828023018425/0001628280-23-018425-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended April 1, 2023"},{"label":"Revenue","value":"$119.1 million"},{"label":"Net income","value":"$100.0 million"},{"label":"EPS","value":"$1.28"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}